Vasopressin (AVP) is not only a potent antidiuretic and vasoconstrictor hormone but it also stimulates platelet aggregation, blood coagulation factors, glucose release, and fibroblast proliferation. All these actions may mediate the involvement of AVP in the development of arterial hypertension and atherosclerosis. To substantiate this working hypothesis and complete our knowledge on AVP regulation and mechanisms of action, we propose to conduct the following research lines: 1) The exploration in normal and hypertensive rats (genetically and DOCA-salt hypertensive models) of the regulation of both types of AVP receptors during alterations of dietary sodium intake, of circulating AVP concentration and of blood pressure. The cellular responsiveness to AVP in these animals will be tested at the vascular (pressor dose-response curve) and renal (adenylate cyclase activity) levels. 2) The study of the interactions of the human platelet AVP receptors with the guanine nucleotide regulatory protein, phospholipase C, phospholipase A2 and the Na+/H+ exchanger. 3) The purification of the human platelet V1 vascular AVP receptor by detergent solubilization, gel chromatography, high pressure liquid chromatography, affinity chromatography, photoaffinity cross linking and amino acid sequencing. The long term objective of our research is to: 1) Determine the role played by AVP in the development of arterial hypertension and atherosclerosis. 2) Clone human AVP receptors and describe the molecular defect present in nephrogenic diabetes insipidus 3) Help to develop orally active drugs antagonizing AVP actions in human diseases such as arterial hypertension, cardiac failure and liver cirrhosis.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Experimental Cardiovascular Sciences Study Section (ECS)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
Schools of Medicine
United States
Zip Code
Wu, Nan; Hanson, Susan M; Francis, Derek J et al. (2006) Arrestin binding to calmodulin: a direct interaction between two ubiquitous signaling proteins. J Mol Biol 364:955-63
Wu, Nan; Macion-Dazard, Rosemarie; Nithianantham, Stanley et al. (2006) Soluble mimics of the cytoplasmic face of the human V1-vascular vasopressin receptor bind arrestin2 and calmodulin. Mol Pharmacol 70:249-58
Macion-Dazard, Rosemarie; Callahan, Nicholas; Xu, Zhen et al. (2006) Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor. J Pharmacol Exp Ther 316:564-71
Adikesavan, Nallini Vijayarangan; Mahmood, Syed Saad; Stanley, Nithianantham et al. (2005) A C-terminal segment of the V1R vasopressin receptor is unstructured in the crystal structure of its chimera with the maltose-binding protein. Acta Crystallogr Sect F Struct Biol Cryst Commun 61:341-5
Thibonnier, Marc (2003) Vasopressin receptor antagonists in heart failure. Curr Opin Pharmacol 3:683-7
Thibonnier, M; Plesnicher, C L; Berrada, K et al. (2001) Role of the human V1 vasopressin receptor COOH terminus in internalization and mitogenic signal transduction. Am J Physiol Endocrinol Metab 281:E81-92
Thibonnier, M; Graves, M K; Wagner, M S et al. (2000) Study of V(1)-vascular vasopressin receptor gene microsatellite polymorphisms in human essential hypertension. J Mol Cell Cardiol 32:557-64
Berrada, K; Plesnicher, C L; Luo, X et al. (2000) Dynamic interaction of human vasopressin/oxytocin receptor subtypes with G protein-coupled receptor kinases and protein kinase C after agonist stimulation. J Biol Chem 275:27229-37
Thibonnier, M; Coles, P; Conarty, D M et al. (2000) A molecular model of agonist and nonpeptide antagonist binding to the human V(1) vascular vasopressin receptor. J Pharmacol Exp Ther 294:195-203
Thibonnier, M; Conarty, D M; Plesnicher, C L (2000) Mediators of the mitogenic action of human V(1) vascular vasopressin receptors. Am J Physiol Heart Circ Physiol 279:H2529-39

Showing the most recent 10 out of 23 publications